Analysis of CYP2C9*5 in Caucasian, Oriental and black-African populations

被引:50
作者
Yasar, Ü
Aklillu, E
Canaparo, R
Sandberg, M
Sayi, J
Roh, HK
Wennerholm, A
机构
[1] Huddinge Univ Hosp, Karolinska Inst, Div Clin Pharmacol, Dept Med Lab Sci & Technol, SE-14186 Stockholm, Sweden
[2] Hacettepe Univ, Fac Med, Dept Pharmacol, TR-06100 Ankara, Turkey
[3] Karolinska Inst, Div Mol Toxicol, IMM, Stockholm, Sweden
[4] Muhimbili Univ Coll Hlth Sci, Dept Clin Pharmacol, Dar Es Salaam, Tanzania
[5] Inha Univ Hosp, Dept Internal Med, Div Clin Pharmacol, Inchon, South Korea
关键词
CYP2C9; polymorphism; CYP2C9*5;
D O I
10.1007/s00228-002-0518-6
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objectives: CYP2C9 is a polymorphic gene with at least six known allelic variants (CYP2C9*1 to *6). CYP2C9*5 has been recently described in African-Americans. The lower activity of CYP2C9*5 encoded enzyme than *1 has been reported for the S-warfarin 7-hydroxylation in vitro. The aim of the present study was to develop an assay for the analysis of this variant and to determine the frequency of this polymorphism in different ethnic populations. Materials and methods: A PCR-based endonuclease digestion method, using a mismatched forward primer that introduced a recognition site for AvaII in all the CYP2C9 genotypes except CYP2C9*5, is described. DNA samples from 150 Ethiopians, 183 Tanzanians, 200 Caucasians from Sweden and 150 Orientals from Korea were screened for this variant allele. Results and conclusion: The CYP2C9*5 allele was analysed using a polymerase chain reaction-based endonuclease method, and it was found in three Tanzanians (allele frequency, 0.0082) but not in Ethiopians, Caucasians or Orientals.
引用
收藏
页码:555 / 558
页数:4
相关论文
共 33 条
  • [1] Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications
    Aithal, GP
    Day, CP
    Kesteven, PJL
    Daly, AK
    [J]. LANCET, 1999, 353 (9154) : 717 - 719
  • [2] Aklillu E, 1996, J PHARMACOL EXP THER, V278, P441
  • [3] Severe phenytoin intoxication in a subject homozygous for CYP2C9*3
    Brandolese, R
    Scordo, MG
    Spina, E
    Gusella, M
    Padrini, R
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 70 (04) : 391 - 394
  • [4] BROCKMOLLER J, 2001, PHARMACOL TOXICOL, V89, P107
  • [5] Identification and functional characterization of a new CYP2C9 variant (CYP2C9*5) expressed among African Americans
    Dickmann, LJ
    Rettie, AE
    Kneller, MB
    Kim, RB
    Wood, AJJ
    Stein, CM
    Wilkinson, GR
    Schwarz, UI
    [J]. MOLECULAR PHARMACOLOGY, 2001, 60 (02) : 382 - 387
  • [6] Cytochrome P450 enzymes in vascular homeostasis
    Fleming, I
    [J]. CIRCULATION RESEARCH, 2001, 89 (09) : 753 - 762
  • [7] Gaedigk A, 2000, CLIN PHARMACOL THER, V67, P168
  • [8] Cytochrome P4502C9 (CYP2C9) allele frequencies in canadian native indian and inuit populations
    Gaedigk, A
    Casley, WL
    Tyndale, RF
    Sellers, EM
    Jurima-Romet, M
    Leeder, JS
    [J]. CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, 2001, 79 (10) : 841 - 847
  • [9] GOTOH O, 1992, J BIOL CHEM, V267, P83
  • [10] HOW SENSITIVE IS PCR-SSCP
    HAYASHI, K
    YANDELL, DW
    [J]. HUMAN MUTATION, 1993, 2 (05) : 338 - 346